MX378503B - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. - Google Patents
Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.Info
- Publication number
- MX378503B MX378503B MX2019010530A MX2019010530A MX378503B MX 378503 B MX378503 B MX 378503B MX 2019010530 A MX2019010530 A MX 2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A MX 378503 B MX378503 B MX 378503B
- Authority
- MX
- Mexico
- Prior art keywords
- mosquitoes
- replication
- attenuated recombinant
- incapable
- equine encephalitis
- Prior art date
Links
- 241000255925 Diptera Species 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000010076 replication Effects 0.000 title 1
- 241000710929 Alphavirus Species 0.000 abstract 3
- 241001502567 Chikungunya virus Species 0.000 abstract 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 abstract 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 1
- 241000710951 Western equine encephalitis virus Species 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 | |
| PCT/US2009/000458 WO2009131604A2 (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010530A MX2019010530A (es) | 2019-10-15 |
| MX378503B true MX378503B (es) | 2025-03-11 |
Family
ID=41217313
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010530A MX378503B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2014010258A MX367792B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010258A MX367792B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (enExample) |
| EP (2) | EP2250269B1 (enExample) |
| JP (1) | JP5758632B2 (enExample) |
| KR (2) | KR101913790B1 (enExample) |
| CN (1) | CN102083986B (enExample) |
| AU (1) | AU2009238667A1 (enExample) |
| CA (2) | CA2713165C (enExample) |
| CO (1) | CO6290702A2 (enExample) |
| IL (2) | IL207167A (enExample) |
| MX (3) | MX378503B (enExample) |
| MY (1) | MY178870A (enExample) |
| NZ (2) | NZ587502A (enExample) |
| SG (2) | SG187513A1 (enExample) |
| WO (1) | WO2009131604A2 (enExample) |
| ZA (1) | ZA201005943B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2947149T3 (en) * | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| JP5758632B2 (ja) | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| US9701719B2 (en) | 2012-09-27 | 2017-07-11 | Research Development Foundation | Attenuated Chikungunya virus |
| US10137186B2 (en) | 2013-03-14 | 2018-11-27 | Takeda Vaccines, Inc. | Compositions and methods for live, attenuated alphavirus formulations |
| EP3436062A1 (en) * | 2016-03-31 | 2019-02-06 | Takeda Vaccines, Inc. | Live, attenuated alphavirus constructs and methods and uses thereof |
| PH12018502460B1 (en) * | 2016-05-27 | 2023-11-08 | Univ Griffith | Arthrogenic alphavirus vaccine |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| KR102823029B1 (ko) | 2017-12-20 | 2025-06-20 | 브이엘피 테라퓨틱스 인코포레이티드 | 알파바이러스 레플리콘 입자 |
| US20210268098A1 (en) * | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| KR102764120B1 (ko) | 2019-12-31 | 2025-02-06 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| EP1608762B1 (en) | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| EP1658744A4 (en) | 2004-07-30 | 2006-09-27 | Research In Motion Ltd | METHOD AND SYSTEM FOR COORDINATING THE PARAMETERS OF A DEVICE BETWEEN A COMMUNICATIONS CLIENT AND HOST DEVICE |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| JP5758632B2 (ja) | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
-
2009
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367792B (es) | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| MX375431B (es) | Virus de la enfermedad de newcastle y usos de los mismos. | |
| CL2016003172A1 (es) | Anticuerpos dirigidos contra cd127 | |
| Garousi | Duality constraints on effective actions | |
| CL2011003273A1 (es) | Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs. | |
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| MX2018011534A (es) | Metodos para transfectar plantas y para reducir eventos de integracion aleatoria. | |
| MX387420B (es) | Producción de virus en cultivos celulares. | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
| MX366154B (es) | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. | |
| MY166879A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| EA201990483A1 (ru) | Композиции, содержащие конкретные поверхностно-активные вещества и высокие содержания глицерина | |
| WO2009048633A3 (en) | Chimeric chikungunya virus and uses thereof | |
| PH12015502115B1 (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| PE20190149A1 (es) | Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas | |
| WO2015019253A3 (en) | Anti-dengue virus genetic vaccine based on the envelope protein ectodomains | |
| BR112015023635A8 (pt) | Composições e métodos para construtos quiméricos de vírus da dengue em vacinas | |
| Nosovets | Media in «VKontakte» social network: structural and content features | |
| Meskhishvili | Be careful, the state threatens to confiscate the land! | |
| Ibragimov | The definition of" legitimacy" and conceptual problems of protecting the rights of the victim in the Russian Criminal Procedure | |
| Murphy | Book Review: Emmaus and Abbé Pierre: An Alternative Model of Enterprise Charity and Society | |
| Liang et al. | Dense High e+/e-Ratio Pair Creation using the Texas Petawatt Laser | |
| Bhaṭṭa | Sāgara, lahareṃ aura manushya | |
| CL2017000073A1 (es) | Agente con propiedades antivirales para prevenir o tratar a individuos expuestos a un virus de la familia birnaviridae |